Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma


Viewing 0 reply threads
  • Author
    • #42808
      Mary Zawadzki

      In this open-label, phase 3 trial, patients were randomly assigned who were previously untreated HLA-A*02:01–positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. Read more here: https://www.nejm.org/doi/full/10.1056/NEJMoa2103485

Viewing 0 reply threads
  • You must be logged in to reply to this topic.